Hypothesis that high levels of PD-L1 in tumor and/or immunological cells in tumor microenvironment may predict clinical response to CPIs with good evidence of correlation in NSCLC, melanoma, renal cell carcinoma. The gene discussed is CD274; the disease is neoplasm.